Literature DB >> 30952739

Satisfaction After Joint-preservation Surgery in Patients With Musculoskeletal Knee Sarcoma Based on Various Scores.

Kensaku Abe1, Norio Yamamoto2, Katsuhiro Hayashi1, Akihiko Takeuchi1, Satoshi Kato1, Shinji Miwa1, Kentaro Igarashi1, Hiroyuki Inatani1, Y U Aoki1, Takashi Higuchi1, Yuta Taniguchi1, Hiroyuki Tsuchiya1.   

Abstract

BACKGROUND/AIM: At our institute, we prioritize joint-preservation whenever possible in cases of musculoskeletal knee sarcoma. This study aimed to evaluate patient satisfaction after joint-preservation surgery using different scales. PATIENTS AND METHODS: Surveys were mailed to 62 patients with musculoskeletal knee sarcoma. We analyzed the responders' data based on the Musculoskeletal Tumor Society (MSTS) score, Toronto Extremity Salvage Score (TESS), and three component scores (physical, mental, and role/social) of the 36-Item Short-Form Health Survey according to whether they belonged to patients in the joint-preservation or in the joint-replacement groups.
RESULTS: The survey response rate was 67.7%. MSTS and TESS scores were higher in the patients in the joint-preservation group than in the joint-replacement group, although the differences lacked statistical significance.
CONCLUSION: Better physical outcomes improve patient satisfaction, as demonstrated by the high satisfaction in the group with joint-preservation. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Patient satisfaction; joint-preservation; musculoskeletal sarcoma; osteosarcoma; patient-based outcome

Mesh:

Year:  2019        PMID: 30952739     DOI: 10.21873/anticanres.13306

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

Review 1.  Joint-preservation surgery for bone sarcoma in adolescents and young adults.

Authors:  Norio Yamamoto; Yoshihiro Araki; Hiroyuki Tsuchiya
Journal:  Int J Clin Oncol       Date:  2022-03-26       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.